Show simple item record

dc.contributor.authorMeyer, Benjamin
dc.contributor.authorReimerink, Johan
dc.contributor.authorTorriani, Giulia
dc.contributor.authorBrouwer, Fion
dc.contributor.authorGodeke, Gert-Jan
dc.contributor.authorYerly, Sabine
dc.contributor.authorHoogerwerf, Marieke
dc.contributor.authorVuilleumier, Nicolas
dc.contributor.authorKaiser, Laurent
dc.contributor.authorEckerle, Isabella
dc.contributor.authorReusken, Chantal
dc.date.accessioned2020-11-13T10:38:24Z
dc.date.available2020-11-13T10:38:24Z
dc.date.issued2020-12-01
dc.identifier.issn2222-1751
dc.identifier.pmid33043818
dc.identifier.doi10.1080/22221751.2020.1835448
dc.identifier.urihttp://hdl.handle.net/10029/624499
dc.language.isoenen_US
dc.subjectSARS-CoV-2en_US
dc.subjectcell-based virus neutralisation assayen_US
dc.subjectneutralising antibodiesen_US
dc.subjectpseudovirus neutralisation assayen_US
dc.subjectsurrogate virus neutralisation assayen_US
dc.titleValidation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT).en_US
dc.typeArticleen_US
dc.identifier.journalEmerg Microbes Infect 2020; 9(1):2394-403en_US
dc.source.journaltitleEmerging microbes & infections


This item appears in the following Collection(s)

Show simple item record